Phase 2 study of the combination of gemcitabine and nedaplation for treatment of previously untreated advanced squamous cell lung cancer
Not Applicable
- Conditions
- ung squamous cell carcinoma
- Registration Number
- JPRN-UMIN000004833
- Lead Sponsor
- First Department of Surgery, Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1) Active infectious disease 2) Patients with fever above 38 degrees. 3) Patients with severe complications. 4) Active concominant malignancies. 5) Patients with symptomatic brain metastasis. 6) Pleural effusion, pericardial effusion and ascites to need treatment 7) Patients with a history of hypersensitivity to the gemcitabine or nedaplation. 8) History of pregnancy or lactation. 9) Patients whose participation in the trial is judged to be inappropriate by the attendeing doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Progression-free survival Overall Survival Toxicity Feasibility(Dose Intensity)